| Entry |
|
|---|
| Name |
EML4-ALK fusion kinase to PI3K signaling pathway
|
|---|
| Definition |
EML4-ALK -> PI3K -> PIP3 -> AKT -| BAD |
|---|
| Expanded |
(238v1,238v2) -> (5290,5291,5293) -> C05981 -> (207,208,10000) -| 572 |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Pathway |
|
|---|
| Disease |
| H00014 | Non-small cell lung cancer |
|
|---|
| Gene |
| 238 | ALK; ALK receptor tyrosine kinase |
| 5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| 5291 | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| 5293 | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| 207 | AKT1; AKT serine/threonine kinase 1 |
| 208 | AKT2; AKT serine/threonine kinase 2 |
| 10000 | AKT3; AKT serine/threonine kinase 3 |
| 572 | BAD; BCL2 associated agonist of cell death |
|
|---|
| Variant |
238v1 (EML4-ALK) EML4-ALK fusion
238v2 (EML4-ALK) First generation TKI-resistant ALK1 mutation
|
|---|
| Metabolite |
| C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
|---|
| Reference |
|
|---|
| Authors |
Roskoski R Jr |
|---|
| Title |
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Janne PA, Gray N, Settleman J |
|---|
| Title |
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Raghav KP, Gonzalez-Angulo AM, Blumenschein GR Jr |
|---|
| Title |
Role of HGF/MET axis in resistance of lung cancer to contemporary management. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Solomon B, Wilner KD, Shaw AT |
|---|
| Title |
Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
